Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren Fiskus

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Endocrine-Related Cancer|October 12, 2021
Inhibition of GATA2 in prostate cancer by a clinically available small moleculeSalma Kaochar, Aleksandra Rusin, Christopher Foley, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood Cancer Journal|January 17, 2019
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cellsWarren Fiskus, Tianyu Cai, Courtney D DiNardo, et al.
Blood|February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitorWarren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Virchows Archiv : an International Journal of Pathology|March 2, 2023
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variantSiba El Hussein, L Jeffrey Medeiros, Stephen K Gruschkus, et al.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Endocrine-Related Cancer|October 12, 2021
Inhibition of GATA2 in prostate cancer by a clinically available small moleculeSalma Kaochar, Aleksandra Rusin, Christopher Foley, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood Cancer Journal|January 17, 2019
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cellsWarren Fiskus, Tianyu Cai, Courtney D DiNardo, et al.
Blood|February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitorWarren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Virchows Archiv : an International Journal of Pathology|March 2, 2023
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variantSiba El Hussein, L Jeffrey Medeiros, Stephen K Gruschkus, et al.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Pageof 10